Alexandre Motta, PhD
Founder and CEO
- Pre-clinical stage
- Patents filed
A new approach to cancer immunotherapy
FOSCA BioTech is developing an implantable medical device for glioblastoma, designed to remove a broad range of cancer-promoting molecules from the tumour microenvironment at the same time. Validated in vitro, currently in pre-clinical testing.
The problem
Tumours suppress the immune system through multiple molecules at once.
Cancer fuels its own growth and escapes the patient's immune system by releasing hundreds of molecular signals in its surrounding fluid, creating the so-called tumour microenvironment. Current single-target therapies block one pathway and leave the others open. The tumour keeps evading the immune system, and resistance follows.
Our solution
The principle of Interstitial ImmunoTherapy (IN'IT)
FOSCA has developed a device designed to target many of these components at once. It is a miniature probe implanted directly in the tumour, designed to extract the soluble components of the local microenvironment.
How it works
One device. Many targets captured together.
A mechanical approach to a problem that single-target drugs cannot resolve on their own.
01
A patented intra-tumour probe
The FOSCA device is a miniature probe that is implanted directly in the tumour and is designed to extract the soluble components of the local microenvironment. To prevent the tumour from quickly recreating its microenvironment, our probe can stay in place and function continuously over periods of several weeks once inserted.
02
Designed to act on the tumour in several ways
By removing a broad range of soluble cancer-promoting molecules and microvesicles at the same time, rather than blocking a single pathway, our probe is designed to act on the tumour in several ways. The aim is to slow tumour growth, reduce invasiveness and metastasis, and allow the immune system to regain access. Because immunosuppressive molecules are also removed, the immune system may then be able to recognise and attack the tumour.
03
Designed without any drug or synthetic molecule
Our probe extracts the tumour microenvironment without any drug or synthetic molecule, relying instead on chemo-physical mechanisms. It is designed to function continuously over several weeks, with the aim of giving the immune system time to regain access to the tumour and mount a response against it.
- Founded 2024
- Lead indication: glioblastoma
- Patent applications filed
- Validated in vitro
- Pre-clinical testing underway
- Regulatory roadmap in place
Milestones
From founding to the clinic
Where we are in the development of our immunotherapy device.
2024Completed
Company founded
FOSCA BioTech is founded and incorporated in France.
Completed
In-vitro validation
The multi-molecular capture approach is validated in vitro.
Completed
Patent applications filed
Core technology protected and patent portfolio is expanding.
Completed
Key partnerships
We collaborate with experts on the 4 pillars of our development: IP, Regulatory, Engineering and Biology.
Underway
Pre-clinical testing
Pre-clinical testing of the device is underway.
Underway
Regulatory pathway
Regulatory journey started and key partnerships established.
Ambition
Towards the clinic
Our ambition: complete the pre-clinical programme and prepare for first-in-human studies in 2029.
Team
A growing team to take FOSCA from lab to clinic.
Lee Morrison
Chief Business Officer
Arnaud Capuzzo
Head of in vitro preclinical programme
Romane Commerçon
PhD candidate, in vivo programme (glioblastoma models, with BRIC)
Loan Angordans
Mechanical engineering apprentice
Partners & supporters
Supported by leading French institutions and research universities.
For partners
Pharma, clinical and research collaboration
Co-development, licensing, pre-clinical and clinical studies, and manufacturing partnerships.
For investors
Investor relations
A patented, multi-target approach supported by French public institutions and research universities.